Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche: Most Of Avastin Business In Europe Is Now Gone

Follows Competition From Biosimilar Bevacizumab Since Last Summer

Executive Summary

Several biosimilars to Roche’s Avastin are now available in Europe following market formation in June last year, adding to Roche’s woes for its legacy oncology drugs, including MabThera/Rituxan and Herceptin.

You may also be interested in...



Amgen’s Mvasi Set For Blockbuster Status With 50% Share In US

Amgen’s biosimilars sales will almost certainly smash through the $2bn barrier in 2021, driven by the strength of its product portfolio including bevacizumab and trastuzumab. The California-based biotech has warned, however, that greater competition will naturally lead to pricing challenges.

Stock Watch: J&J And Roche Invite Comparison

Recovering pharmaceutical and medical device revenues at J&J hint at the green shoots germinating from the pandemic. Roche’s COVID-19 diagnostics revenue growth was its own green shoot, but can these be maintained as the pandemic evolves?

Biocon And Viatris Ready To Launch EU Bevacizumab

Viatris and Biocon Biologics are now in a position to enter the European market for biosimilar bevacizumab, after the European Commission formally approved the pair’s Abevmy rival to Avastin.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel